H
Harlan M. Krumholz
Researcher at Yale University
Publications - 1966
Citations - 177853
Harlan M. Krumholz is an academic researcher from Yale University. The author has contributed to research in topics: Myocardial infarction & Population. The author has an hindex of 85, co-authored 1826 publications receiving 159216 citations. Previous affiliations of Harlan M. Krumholz include Veterans Health Administration & Robert Wood Johnson Foundation.
Papers
More filters
Journal ArticleDOI
The prognostic importance of anemia in patients with heart failure
TL;DR: It is found that anemia is associated with an increased risk of death and rehospitalization in older patients with heart failure and lower hematocrits were also associated with a greater risk of hospital readmission.
Journal ArticleDOI
Achieving Rapid Door-To-Balloon Times How Top Hospitals Improve Complex Clinical Systems
Elizabeth H. Bradley,Leslie A. Curry,Tashonna R. Webster,Jennifer A. Mattera,Sarah A. Roumanis,Martha J. Radford,Robert L. McNamara,Barbara A. Barton,David N. Berg,Harlan M. Krumholz +9 more
TL;DR: This study provides a foundation for future efforts to elevate clinical performance in the hospital setting by distilling the complex and diverse experiences of organizational change into its essential components.
Journal ArticleDOI
Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure?
Grace L. Smith,Viola Vaccarino,Mikhail Kosiborod,Judith H. Lichtman,Susan Cheng,Susan Cheng,Suzanne Watnick,Suzanne Watnick,Harlan M. Krumholz,Harlan M. Krumholz +9 more
TL;DR: Larger creatinine elevations predict highest risk of death, yet even minor changes in renal function are associated with adverse outcomes, suggesting the choice of a “best definition” for worsening renal function has implications for the number of patients identified with this risk factor and the magnitude of risk for mortality.
Journal ArticleDOI
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction
TL;DR: End-stage renal disease patients are far less likely than non-ESRD patients to be treated with aspirin, beta-blockers, and ACE inhibitors during an admission for AMI, suggesting lower rates of usage for these medications may contribute to the increased 30-day mortality.
Journal ArticleDOI
Quality of primary health care in China: challenges and recommendations.
Xi Li,Harlan M. Krumholz,Winnie Yip,Kar Keung Cheng,Kar Keung Cheng,Jan De Maeseneer,Qingyue Meng,Elias Mossialos,Chuang Li,Jiapeng Lu,Meng Su,Qiuli Zhang,Qiuli Zhang,Dong Xu,Liming Li,Sharon-Lise T. Normand,Sharon-Lise T. Normand,Richard Peto,Jing Li,Zengwu Wang,Hongbing Yan,Runlin Gao,Somsak Chunharas,Xin Gao,Raniero Guerra,Huijie Ji,Yang Ke,Zhigang Pan,Xianping Wu,Shuiyuan Xiao,Xinying Xie,Yujuan Zhang,Jun Zhu,Shanzhu Zhu,Shengshou Hu +34 more
TL;DR: China has substantially increased financial investment and introduced favourable policies for strengthening its primary health care system with core responsibilities in preventing and managing chronic diseases such as hypertension and emerging infectious disease 2019 (COVID-19).